46 results on '"Cortes, Jorge E."'
Search Results
2. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia
- Author
-
Short, Nicholas J, Kantarjian, Hagop, Ravandi, Farhad, Huang, Xuelin, Xiao, Lianchun, Garcia-Manero, Guillermo, Plunkett, William, Gandhi, Varsha, Sasaki, Koji, Pemmaraju, Naveen, Daver, Naval G, Borthakur, Gautam, Jain, Nitin, Konopleva, Marina, Estrov, Zeev, Kadia, Tapan M, Wierda, William G, DiNardo, Courtney D, Brandt, Mark, O’Brien, Susan M, Cortes, Jorge E, and Jabbour, Elias
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Oncology and Carcinogenesis ,Rare Diseases ,Clinical Research ,Clinical Trials and Supportive Activities ,Cancer ,Hematology ,Pediatric ,Pediatric Cancer ,Childhood Leukemia ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Adult ,Aged ,Antineoplastic Combined Chemotherapy Protocols ,Bone Marrow ,Clofarabine ,Cytarabine ,Drug Resistance ,Neoplasm ,Humans ,Idarubicin ,Leukemia ,Myeloid ,Acute ,Middle Aged ,Neoplasm Recurrence ,Local ,Progression-Free Survival ,Remission Induction ,Survival Rate ,Treatment Outcome ,Vidarabine ,Young Adult ,Acute myeloid leukemia ,relapsed ,refractory ,purine nucleoside analogues ,clofarabine ,fludarabine ,Clinical Sciences ,Immunology ,Cardiovascular medicine and haematology - Abstract
The purine nucleoside analogues clofarabine and fludarabine are active in acute myeloid leukemia (AML). We conducted a phase I/II randomized study of idarubicin and cytarabine with either clofarabine (CIA) or fludarabine (FIA) for relapsed or refractory AML. Clofarabine 15 mg/m2 was identified as the recommended phase II dose. Eighty-one patients were assigned using adaptive randomization to CIA (n = 48) or FIA (n = 33). The complete response (CR)/CR without platelet recovery rate did not differ between CIA and FIA (38% versus 30%, respectively; p = .50). In both arms, more than half of patients who had received only one prior line of therapy achieved remission. The median event-free survival for CIA and FIA was 2.0 and 1.9 months (p = .48), and the median overall survival was 6.3 and 4.7 months, respectively (p = .28). No significant differences in adverse events or early mortality rates were observed. Overall, CIA and FIA resulted in similar response rates and survival in patients with relapsed/refractory AML.
- Published
- 2018
3. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia
- Author
-
Jabbour, Elias, Short, Nicholas J, Ravandi, Farhad, Huang, Xuelin, Xiao, Lianchun, Garcia‐Manero, Guillermo, Plunkett, William, Gandhi, Varsha, Sasaki, Koji, Pemmaraju, Naveen, Daver, Naval G, Borthakur, Gautam, Jain, Nitin, Konopleva, Marina, Estrov, Zeev, Kadia, Tapan M, Wierda, William G, DiNardo, Courtney D, Brandt, Mark, O'Brien, Susan M, Cortes, Jorge E, and Kantarjian, Hagop
- Subjects
Pediatric ,Rare Diseases ,Hematology ,Cancer ,Clinical Trials and Supportive Activities ,Childhood Leukemia ,Pediatric Cancer ,Patient Safety ,Clinical Research ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Good Health and Well Being ,Adenine Nucleotides ,Adolescent ,Adult ,Aged ,Antineoplastic Combined Chemotherapy Protocols ,Arabinonucleosides ,Clofarabine ,Cytarabine ,Humans ,Idarubicin ,Leukemia ,Myeloid ,Acute ,Middle Aged ,Neoadjuvant Therapy ,Treatment Outcome ,Vidarabine ,Young Adult ,acute myeloid leukemia ,clofarabine ,fludarabine ,induction ,nucleoside analog ,Oncology and Carcinogenesis ,Public Health and Health Services ,Oncology & Carcinogenesis - Abstract
BackgroundFludarabine and clofarabine are purine nucleoside analogues with established clinical activity in patients with acute myeloid leukemia (AML).MethodsHerein, the authors evaluated the efficacy and safety of idarubicin and cytarabine with either clofarabine (CIA) or fludarabine (FIA) in adults with newly diagnosed AML. Adults with newly diagnosed AML who were deemed suitable for intensive chemotherapy were randomized using a Bayesian adaptive design to receive CIA (106 patients) or FIA (76 patients). Patients received induction with idarubicin and cytarabine, plus either clofarabine or fludarabine. Responding patients could receive up to 6 cycles of consolidation therapy. Outcomes were compared with a historical cohort of patients who received idarubicin and cytarabine.ResultsThe complete remission/complete remission without platelet recovery rate was similar among patients in the CIA and FIA arms (80% and 82%, respectively). The median event-free survival was 13 months and 12 months, respectively (P = .91), and the median overall survival was 24 months and not reached, respectively (P = .23), in the 2 treatment arms. CIA was associated with more adverse events, particularly transaminase elevation, hyperbilirubinemia, and rash. Early mortality was similar in the 2 arms (60-day mortality rate of 4% for CIA vs 1% for FIA; P = .32). In an exploratory analysis of patients aged
- Published
- 2017
4. Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial
- Author
-
Heuser, Michael, Smith, B. Douglas, Fiedler, Walter, Sekeres, Mikkael A., Montesinos, Pau, Leber, Brian, Merchant, Akil, Papayannidis, Cristina, Pérez-Simón, José A., Hoang, Caroline J., O’Brien, Thomas, Ma, Weidong Wendy, Zeremski, Mirjana, O’Connell, Ashleigh, Chan, Geoffrey, and Cortes, Jorge E.
- Published
- 2021
- Full Text
- View/download PDF
5. Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML
- Author
-
Cortes, Jorge E., Lin, Tara L., Uy, Geoffrey L., Ryan, Robert J., Faderl, Stefan, and Lancet, Jeffrey E.
- Published
- 2021
- Full Text
- View/download PDF
6. Phase II, multicenter, randomized trial of CPX‐351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML
- Author
-
Cortes, Jorge E, Goldberg, Stuart L, Feldman, Eric J, Rizzeri, David A, Hogge, Donna E, Larson, Melissa, Pigneux, Arnaud, Recher, Christian, Schiller, Gary, Warzocha, Krzysztof, Kantarjian, Hagop, Louie, Arthur C, and Kolitz, Jonathan E
- Subjects
Childhood Leukemia ,Pediatric ,Clinical Trials and Supportive Activities ,Clinical Research ,Hematology ,Pediatric Cancer ,Cancer ,Rare Diseases ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Adult ,Aged ,Aminoglycosides ,Amsacrine ,Antibodies ,Monoclonal ,Humanized ,Antineoplastic Combined Chemotherapy Protocols ,Cladribine ,Cytarabine ,Daunorubicin ,Disease-Free Survival ,Etoposide ,Female ,Gemtuzumab ,Humans ,Injections ,Kaplan-Meier Estimate ,Leukemia ,Myeloid ,Acute ,Liposomes ,Male ,Middle Aged ,Mitoxantrone ,Recurrence ,Remission Induction ,Risk Assessment ,Salvage Therapy ,Treatment Outcome ,Vidarabine ,Acute Myeloid Leukemia ,Phase II ,First Relapse ,Chemotherapy Intervention ,Oncology and Carcinogenesis ,Public Health and Health Services ,Oncology & Carcinogenesis - Abstract
BackgroundCPX-351 is a liposome-encapsulated fixed-molar-ratio formulation of cytarabine and daunorubicin that exploits molar ratio-dependent drug-drug synergy to enhance antileukemic efficacy.MethodsThis phase II study randomized 125 patients 2:1 to CPX-351 or investigators' choice of first salvage chemotherapy. Patients with acute myeloid leukemia (AML) in first relapse after initial Complete Remission (CR) lasting ≥1 month were stratified per the European Prognostic Index (EPI) into favorable, intermediate, and poor-risk groups based on duration of first CR, cytogenetics, age, and transplant history. Control salvage treatment was usually based on cytarabine and anthracycline, often with 1 or more additional agents. Survival at 1 year was the primary efficacy end point.ResultsPatient characteristics were well balanced between the 2 study arms. Improvements in efficacy outcomes were observed following CPX-351, but did not meet prospectively defined statistical criteria for 1-year survival improvement in the overall population. Subset analyses of the EPI-defined poor-risk strata demonstrated higher response rates (39.3% vs 27.6%) and improvements in event-free survival (HR, 0.63; P = .08) and overall survival (HR, 0.55; P = .02). Also, 60-day mortality was lower in the CPX-351 study arm for poor-risk patients (16.1% vs 24.1%).ConclusionsTaken together, the data suggest possible improved outcomes in CPX-351-treated first relapse AML patients with EPI-defined poor-risk disease.
- Published
- 2015
7. Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia
- Author
-
Cortes, Jorge E., de Lima, Marcos, Dombret, Hervé, Estey, Elihu H., Giralt, Sergio A., Montesinos, Pau, Röllig, Christoph, Venditti, Adriano, and Wang, Eunice S.
- Published
- 2020
- Full Text
- View/download PDF
8. Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high‐risk myelodysplastic syndrome
- Author
-
Lahoti, Amit, Kantarjian, Hagop, Salahudeen, Abdulla K, Ravandi, Farhad, Cortes, Jorge E, Faderl, Stefan, O'Brien, Susan, Wierda, William, and Mattiuzzi, Gloria N
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Rare Diseases ,Pediatric ,Hematology ,Cancer ,Childhood Leukemia ,Pediatric Cancer ,Kidney Disease ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Renal and urogenital ,Good Health and Well Being ,Acute Kidney Injury ,Adolescent ,Adult ,Aged ,Aged ,80 and over ,Female ,Humans ,Kidney Function Tests ,Leukemia ,Myeloid ,Acute ,Male ,Middle Aged ,Myelodysplastic Syndromes ,Prognosis ,Risk Factors ,acute kidney failure ,acute myeloid leukemia ,myelodysplastic syndrome ,dialysis ,logistic models ,Oncology and Carcinogenesis ,Public Health and Health Services ,Oncology & Carcinogenesis ,Oncology and carcinogenesis ,Public health - Abstract
Background: Acute kidney injury (AKIis a common complication in the treatment of patients with acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS), but, to the authors' knowledge, its clinical relevance has not been detailed to date. The objective of the current study was to identify the incidence, predictors, and outcome for AKI in patients with AML and HR-MDS.Methods: Data were analyzed from 537 patients with AML or HR-MDS undergoing induction chemotherapy from 1999 to 2007. Predictors for AKI were identified by logistic regression. Eight-week mortality of patients was estimated by the Kaplan-Meier method stratified by the RIFLE criteria, a novel multilevel classification system for AKI based on the percent rise in serum creatinine from baseline (Risk, >50%; Injury, >100%; and Failure, >200% or requiring dialysis).Results: A total of 187 patients (36%) developed AKI. Significant independent risk factors for AKI included the following: age >/=55 years (odds ratio [OR], 1.8), mechanical ventilation (OR, 16), use of vancomycin (OR, 2.3), diuretics (OR, 3.0), amphotericin B lipid formulation (OR, 2.7), vasopressors (OR, 4.9), leukopenia (OR, 1.9), hypoalbuminemia (OR, 1.4), and use of non-fludarabine-based chemotherapy (OR, 2.7). The 8-week mortality rates were 3.8%, 13.6%, 19.6%, and 61.7% for the non-RIFLE, Risk, Injury, and Failure categories, respectively. Patients requiring dialysis (8%) had a median survival of 33 days. Survival of patients who achieved complete remission was favorable, regardless of degree of AKI.Conclusions: The RIFLE classification for AKI appears to have prognostic utility in predicting mortality in patients with AML or HR-MDS. Relatively mild elevations in creatinine are associated with higher mortality. Strategies to avoid nephrotoxic drugs or fluid overload may be of benefit. Cancer 2010. (c) 2010 American Cancer Society.
- Published
- 2010
9. Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy
- Author
-
Cortes, Jorge E., Heidel, Florian H., Fiedler, Walter, Smith, B. Douglas, Robak, Tadeusz, Montesinos, Pau, Candoni, Anna, Leber, Brian, Sekeres, Mikkael A., Pollyea, Daniel A., Ferdinand, Roxanne, Ma, Weidong Wendy, O’Brien, Thomas, O’Connell, Ashleigh, Chan, Geoffrey, and Heuser, Michael
- Published
- 2020
- Full Text
- View/download PDF
10. Phase 2 study of lenalidomide maintenance for patients with high‐risk acute myeloid leukemia in remission.
- Author
-
Abou Dalle, Iman, Kantarjian, Hagop M., Ravandi, Farhad, Daver, Naval, Wang, Xuemei, Jabbour, Elias, Estrov, Zeev, DiNardo, Courtney D., Pemmaraju, Naveen, Ferrajoli, Alessandra, Jain, Nitin, Wang, Sa A., Jammal, Nadya, Borthakur, Gautam, Naqvi, Kiran, Pelletier, Sarah, Pierce, Sherry, Andreeff, Michael, Garcia‐Manero, Guillermo, and Cortes, Jorge E.
- Subjects
ACUTE myeloid leukemia ,STEM cell transplantation ,LENALIDOMIDE - Abstract
Background: New drug combinations have led to significant improvements in remission rates for patients with acute myeloid leukemia (AML). However, many patients with high‐risk AML who respond to their initial treatment and are not candidates for allogeneic stem cell transplantation (ASCT) will eventually relapse with poor outcomes. Methods: In this phase 2 trial, the efficacy of lenalidomide maintenance was evaluated in patients with high‐risk AML who had achieved their first or second remission after induction chemotherapy and at least 1 consolidation cycle and who were not candidates for immediate ASCT. Lenalidomide was given orally at 10 to 20 mg daily on days 1 to 28 of a 28‐day cycle for up to 24 cycles. Results: A total of 28 patients were enrolled in this study with a median age of 61 years (range, 24‐87 years). The median number of cycles was 8 (range, 1‐24 cycles). Ten patients (36%) completed 24 months of maintenance treatment. With a median follow‐up of 22.5 months (range, 2.6‐55 months), 12 patients (43%) relapsed after a median of 3 months (range, 0.7‐23 months). The median duration of remission for all patients was 18.7 months (range, 0.7‐55.1 months). The 2‐year overall survival and relapse‐free survival rates from the time of enrollment were 63% and 50%, respectively. Overall, lenalidomide was well tolerated; serious adverse events of grade 3 or 4, including rash (n = 5), thrombocytopenia (n = 4), neutropenia (n = 4), and fatigue (n = 2), were observed in 13 patients (46%). Conclusions: Lenalidomide is a safe and feasible maintenance strategy in patients with high‐risk AML who are not candidates for ASCT, and it has beneficial effects for patients with negative measurable residual disease. Lenalidomide maintenance in patients with high‐risk acute myeloid leukemia results in a 2‐year overall survival rate of 63%. The beneficial effect is most profound in patients with negative minimal residual disease and in those without a history of prior myeloid or nonmyeloid neoplasms. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review.
- Author
-
Cortes, Jorge E., Candoni, Anna, Clark, Richard E., Leber, Brian, Montesinos, Pau, Vyas, Paresh, Zeidan, Amer M., and Heuser, Michael
- Subjects
- *
ACUTE myeloid leukemia , *OLDER patients , *CYTARABINE , *PATIENT education , *COMORBIDITY - Abstract
Glasdegib, in combination with low-dose cytarabine (LDAC), is the first smoothened inhibitor approved for treatment of acute myeloid leukemia. Glasdegib plus LDAC is indicated for patients in whom therapy options are limited, e.g. older patients and those ineligible for intensive chemotherapy due to preexisting comorbidities. This review summarizes the recommendations of a panel of hemato-oncologists regarding the selection of patients best suited for treatment with glasdegib plus LDAC and the management during therapy with this combination. The panel considered the impact of concomitant medications and comorbidities during treatment with glasdegib plus LDAC, and discussed common adverse events (AEs) associated with glasdegib plus LDAC. Management strategies for AEs discussed by the panel included dose modifications, supportive care therapies, and prophylactic treatments. Finally, the panel highlighted the importance of patient communication and education regarding the possible AEs that may occur during treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
12. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias.
- Author
-
Maiti, Abhishek, Franquiz, Miguel J., Ravandi, Farhad, Cortes, Jorge E., Jabbour, Elias J., Sasaki, Koji, Marx, Kayleigh, Daver, Naval G., Kadia, Tapan M., Konopleva, Marina Y., Masarova, Lucia, Borthakur, Gautam, DiNardo, Courtney D., Naqvi, Kiran, Pierce, Sherry, Kantarjian, Hagop M., and Short, Nicholas J.
- Subjects
MYELOID leukemia ,PROTEIN-tyrosine kinases ,CHRONIC myeloid leukemia ,ACUTE myeloid leukemia ,KINASE inhibitors - Abstract
Background: Philadelphia chromosome-positive (Ph+) advanced leukemias, including acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) in myeloid blast phase (MBP), have poor outcomes. Venetoclax has shown synergism with BCR-ABL1 tyrosine kinase inhibitors (TKI) in preclinical studies. However, clinical activity of venetoclax and TKI-based regimens is unknown. Methods: We conducted a retrospective study on patients with Ph+ AML (n = 7) and CML-MBP (n = 9) who received venetoclax combined with TKI-based regimens at our institution. Results: Median patient age was 42 years, and the median number of prior therapy cycles was 5 (range 2–8). Nine patients received decitabine-based, and 7 received intensive chemotherapy-based regimens. Ten patients (63%) received ponatinib. The overall response rate (ORR) in 15 evaluable patients was 60% (1 complete remission [CR], 6 CR with incomplete hematologic recovery [CRi], 1 morphologic leukemia-free state, and 1 partial response). The ORR was 43% in Ph+ AML and 75% in CML-MBP. The median overall survival (OS) for all patients was 3.6 months, for AML OS was 2.0 months, and for CML-MBP OS was 10.9 months. The median relapse-free survival for AML and CML-MBP was 3.6 and 3.9 months, respectively. Compared to nonresponders, patients achieving CR/CRi had higher baseline Ph+ metaphases and BCR-ABL1 PCR. Conclusions: Combination therapy of venetoclax with TKI-based regimens shows encouraging activity in very heavily pretreated, advanced Ph+ leukemias, particularly CML-MBP. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
13. A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy.
- Author
-
Solem, Caitlyn T., Bell, Timothy J., Kwon, Youngmin, Cappelleri, Joseph C., Johnson, Courtney, Bhattacharyya, Helen, Hoang, Caroline J., and Cortes, Jorge E.
- Subjects
ACUTE myeloid leukemia ,SYMPTOMS ,TERMINATION of treatment ,CANCER chemotherapy ,DISEASE progression ,THERAPEUTIC use of antineoplastic agents ,RESEARCH ,UREA ,HETEROCYCLIC compounds ,RESEARCH methodology ,ANTINEOPLASTIC agents ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,SURVIVAL analysis (Biometry) ,RESEARCH funding ,CYTARABINE ,PHARMACODYNAMICS - Abstract
Background: In a randomized study, glasdegib (a hedgehog inhibitor) plus low-dose cytarabine (LDAC) significantly prolonged survival in comparison with LDAC in patients with acute myeloid leukemia (AML). A quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) approach was used to evaluate comparative quality-adjusted survival.Methods: Overall survival was partitioned into the following: time with any treatment-emergent grade 3 or higher adverse events (TOX); time without symptoms of disease progression or toxicity (TWiST); and time after treatment discontinuation due to insufficient clinical response, relapse, or death time after progression (REL). Q-TWiST was calculated by multiplying the restricted mean time in each state by respective utilities and then summing up the utility-adjusted time.Results: At 20 months of follow-up, the survival probabilities for the glasdegib-LDAC arm and the LDAC arm were 28.2% and 7.9%, respectively. Glasdegib-LDAC patients (n = 78), in comparison with LDAC patients (n = 38), had significantly longer mean TWiST (+3.4 months; 95% confidence interval [CI], 1.8-5.2 months) and TOX (+0.8 months; 95% CI, 0.1-1.6 months) and longer but nonsignificant REL (+0.3 months; 95% CI, -1.9 to 2.3 months). Q-TWiST was 4.0 months (95% CI, 2.1-5.8 months) longer with glasdegib plus LDAC, and this translated into a 75% relative improvement in quality-adjusted survival with respect to LDAC. Results were robust to the length of follow-up (6-24 months) and remained significant when all adverse events, regardless of grade, were included.Conclusions: These results suggest that most of the survival benefit from glasdegib plus LDAC versus LDAC alone is TWiST, and this represents added time in relatively "good" health. These results support the clinical value of glasdegib plus LDAC as initial therapy for AML in patients for whom intensive chemotherapy is not an option. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
14. An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure.
- Author
-
Lin, Swan, Shaik, Naveed, Chan, Geoffrey, Cortes, Jorge E., and Ruiz-Garcia, Ana
- Subjects
ACUTE myeloid leukemia ,OLDER patients ,EXPOSURE dose ,LABORATORY safety ,PHARMACOKINETICS ,DEMOGRAPHIC characteristics - Abstract
Purpose: Glasdegib, an oral inhibitor of the Hedgehog signaling pathway, is approved in the United States in combination with low-dose cytarabine (LDAC) to treat patients with newly diagnosed acute myeloid leukemia (AML) ineligible to receive intensive chemotherapy. This population pharmacokinetic/pharmacodynamic analysis characterized the time course of survival with glasdegib + LDAC relative to LDAC alone, and explored whether the differences in glasdegib exposure at the clinical dose of 100 mg once daily (QD) significantly affected overall survival (OS). Methods: Data from the BRIGHT AML 1003 trial in patients with AML were included in treatment–response (glasdegib + LDAC, n = 78; LDAC alone, n = 38) and exposure–response (glasdegib + LDAC, n = 75) analyses. Results: The analyses demonstrate that patients treated with glasdegib + LDAC (vs LDAC alone) at any time point during the study period were 58% less likely to die, translating to prolonging of median OS by ~ 5 months (hazard ratio 0.42 [95% confidence interval 0.28–0.66]). Variability in glasdegib exposures did not impact the risk of death. Additionally, potential covariates such as patient demographics, prior treatment with a hypomethylating agent, baseline safety laboratory values, and disease characteristics, did not impact the probability of OS. Conclusion: Together these results confirm that glasdegib + LDAC treatment (vs. LDAC alone) is associated with a significant survival benefit in patients with newly diagnosed AML, and that variability in glasdegib doses (e.g., for dose reductions) and exposures do not compromise the survival benefit of glasdegib 100 mg QD. Clinical Trial number: NCT01546038. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
15. Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia.
- Author
-
Kolitz, Jonathan E., Strickland, Stephen A., Cortes, Jorge E., Hogge, Donna, Lancet, Jeffrey E., Goldberg, Stuart L., Villa, Kathleen F., Ryan, Robert J., Chiarella, Michael, Louie, Arthur C., Ritchie, Ellen K., and Stuart, Robert K.
- Subjects
ACUTE myeloid leukemia ,OLDER patients - Abstract
CPX-351 is a dual-drug liposomal encapsulation of cytarabine/daunorubicin. In a phase 3 study (ClinicalTrials.gov Identifier: NCT01696084), patients aged 60–75 years with newly diagnosed, high-risk/secondary AML received 1–2 induction cycles with CPX-351 or 7 + 3 chemotherapy; those achieving complete remission (including with incomplete platelet or neutrophil recovery) could receive up to 2 consolidation cycles with CPX-351 or 5 + 2 chemotherapy, respectively. In this exploratory analysis of the subgroup of patients who received consolidation, median overall survival was prolonged among patients receiving CPX-351 induction/consolidation versus 7 + 3/5 + 2 (25.43 vs. 8.53 months; HR = 0.44 [95% CI: 0.25–0.77]). The safety profile of CPX-351 consolidation was consistent with that of the overall study. Outpatient administration of CPX-351 consolidation occurred in 51%–61% of patients and did not diminish overall survival. These findings suggest consolidation with CPX-351 in this patient population contributed to the prolonged overall survival versus 7 + 3/5 + 2, building upon findings from the overall study population, and provide evidence that, with careful monitoring, some patients can successfully receive CPX-351 as outpatients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
16. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.
- Author
-
Sasaki, Koji, Kantarjian, Hagop M., Kadia, Tapan, Patel, Keyur, Loghavi, Sanam, Garcia‐Manero, Guillermo, Jabbour, Elias J., DiNardo, Courtney, Pemmaraju, Naveen, Daver, Naval, Dalle, Iman Abou, Short, Nicholas, Yilmaz, Musa, Bose, Prithviraj, Naqvi, Kiran, Pierce, Sherry, Yalniz, Fevzi, Cortes, Jorge E., Ravandi, Farhad, and Garcia-Manero, Guillermo
- Subjects
ACUTE myeloid leukemia ,SORAFENIB ,STEM cell transplantation ,PROPORTIONAL hazards models ,PROPENSITY score matching ,PRELEUKEMIA - Abstract
Background: The addition of midostaurin to induction chemotherapy improves survival in younger patients with newly diagnosed, FLT3-mutated acute myeloid leukemia (AML). Sorafenib is a potent multikinase inhibitor with efficacy when given as monotherapy. The authors investigated whether the addition of sorafenib to intensive induction chemotherapy improves outcomes in patients with FLT3-internal tandem duplication (ITD)-mutated AML.Methods: In total, 183 patients who were newly diagnosed with FLT3-ITD-mutated AML between February 2001 and December 2017 were identified. Of these, 79 patients (43%) underwent intensive chemotherapy with the addition of sorafenib, and 104 (57%) received intensive chemotherapy alone. Propensity score matching identified 42 patients in each cohort.Results: The overall response rate was 98% in the sorafenib cohort and 83% in the intensive chemotherapy cohort (P = .057). The median follow-up was 54 months. The median event-free survival was 35 months in the sorafenib cohort and 8 months in the intensive chemotherapy cohort (P = .019), and the median overall survival was 42 and 13 months, respectively (P = .026). With censoring at the time of allogeneic stem cell transplantation, the median event-free survival was 31 and 8 months in the sorafenib and intensive therapy cohorts, respectively (P = .031), and the median overall survival was not reached and 10 months, respectively (P = .001). Multivariate Cox proportional hazards models confirmed that treatment with sorafenib was a favorable prognostic factor (P = .009; hazard ratio, 0.558; 95% CI, 0.360-0.865).Conclusions: The addition of sorafenib improves survival in patients with FLT3-ITD-mutated AML regardless of whether they undergo allogeneic stem cell transplantation. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
17. Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials.
- Author
-
Cortes, Jorge E, Dombret, Hervé, Merchant, Akil, Tauchi, Tetsuzo, DiRienzo, Christine G, Sleight, Barbara, Zhang, Xiaoxi, Leip, Eric P, Shaik, Naveed, Bell, Timothy, Chan, Geoffrey, and Sekeres, Mikkael A
- Abstract
Glasdegib, an oral Hedgehog pathway inhibitor, has been associated with significantly improved survival when combined with low-dose cytarabine in patients with untreated acute myeloid leukemia (AML) who were unsuitable for intensive chemotherapy, when compared with low-dose cytarabine alone. BRIGHT AML 1019 (NCT03416179) comprises two independently powered Phase III, randomized (1:1), double-blind global trials evaluating oral glasdegib 100 mg once daily or placebo plus one of two standard chemotherapy regimens in adults with untreated AML. The intensive trial combines glasdegib/placebo with cytarabine and daunorubicin (7 + 3), while the nonintensive trial combines glasdegib/placebo with azacitidine. The primary end point of both studies is overall survival. Secondary end points include response, time to and duration of response, event-free survival, safety, patient-reported outcomes and pharmacokinetics. Trial registration number: ClinicalTrials.gov identifier: NCT03416179. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
18. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.
- Author
-
Williams, Patrick, Basu, Sreyashi, Garcia‐Manero, Guillermo, Hourigan, Christopher S., Oetjen, Karolyn A., Cortes, Jorge E., Ravandi, Farhad, Jabbour, Elias J., Al‐Hamal, Zainab, Konopleva, Marina, Ning, Jing, Xiao, Lianchun, Hidalgo Lopez, Juliana, Kornblau, Steve M., Andreeff, Michael, Flores, Wilmer, Bueso‐Ramos, Carlos, Blando, Jorge, Galera, Pallavi, and Calvo, Katherine R.
- Subjects
ACUTE myeloid leukemia ,BONE marrow cells ,OLIGODENDROGLIOMAS ,TUMOR necrosis factors ,APOPTOSIS ,ISOCITRATE dehydrogenase ,ACUTE myeloid leukemia diagnosis ,BONE marrow ,CANCER invasiveness ,CELL receptors ,COMPARATIVE studies ,GENES ,IMMUNOHISTOCHEMISTRY ,IMMUNOPHENOTYPING ,LIGANDS (Biochemistry) ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,T cells ,PHENOTYPES ,DISEASE relapse ,EVALUATION research ,CASE-control method ,LYMPHOCYTE count - Abstract
Background: Phenotypic characterization of immune cells in the bone marrow (BM) of patients with acute myeloid leukemia (AML) is lacking.Methods: T-cell infiltration was quantified on BM biopsies from 13 patients with AML, and flow cytometry was performed on BM aspirates (BMAs) from 107 patients with AML who received treatment at The University of Texas MD Anderson Cancer Center. The authors evaluated the expression of inhibitory receptors (programmed cell death protein 1 [PD1], cytotoxic T-lymphocyte antigen 4 [CTLA4], lymphocyte-activation gene 3 [LAG3], T-cell immunoglobulin and mucin-domain containing-3 [TIM3]) and stimulatory receptors (glucocorticoid-induced tumor necrosis factor receptor-related protein [GITR], OX40, 41BB [a type 2 transmembrane glycoprotein receptor], inducible T-cell costimulatory [ICOS]) on T-cell subsets and the expression of their ligands (41BBL, B7-1, B7-2, ICOSL, PD-L1, PD-L2, and OX40L) on AML blasts. Expression of these markers was correlated with patient age, karyotype, baseline next-generation sequencing for 28 myeloid-associated genes (including P53), and DNA methylation proteins (DNA methyltransferase 3α, isocitrate dehydrogenase 1[IDH1], IDH2, Tet methylcytosine dioxygenase 2 [TET2], and Fms-related tyrosine kinase 3 [FLT3]).Results: On histochemistry evaluation, the T-cell population in BM appeared to be preserved in patients who had AML compared with healthy donors. The proportion of T-regulatory cells (Tregs) in BMAs was higher in patients with AML than in healthy donors. PD1-positive/OX40-positive T cells were more frequent in AML BMAs, and a higher frequency of PD1-positive/cluster of differentiation 8 (CD8)-positive T cells coexpressed TIM3 or LAG3. PD1-positive/CD8-positive T cells were more frequent in BMAs from patients who had multiply relapsed AML than in BMAs from those who had first relapsed or newly diagnosed AML. Blasts in BMAs from patients who had TP53-mutated AML were more frequently positive for PD-L1.Conclusions: The preserved T-cell population, the increased frequency of regulatory T cells, and the expression of targetable immune receptors in AML BMAs suggest a role for T-cell-harnessing therapies in AML. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
19. Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.
- Author
-
Boddu, Prajwal, Borthakur, Gautam, Koneru, Mythili, Huang, Xuelin, Naqvi, Kiran, Wierda, William, Bose, Prithviraj, Jabbour, Elias, Estrov, Zeev, Burger, Jan, Alvarado, Yesid, Dekmush, April, Patel, Ami, Cavazos, Antonio, Han, Lina, Cortes, Jorge E., Kantarjian, Hagop, Andreeff, Michael, and Konopleva, Marina
- Subjects
IDARUBICIN ,ACUTE myeloid leukemia treatment ,CYTARABINE ,DISEASE relapse ,DRUG toxicity - Abstract
Background: The CXCR4/SDF-1α axis plays a vital role in the retention of stem cells within the bone marrow and downstream activation of cell survival signaling pathways. LY2510924, a second generation CXCR4, showed significant anti-leukemia activity in a murine AML model. Methods: We conducted a phase I study to determine the safety and toxicity of LY2510924, idarubicin and cytarabine (IA) combination therapy in relapsed/refractory (R/R) AML. Eligible patients were 18–70 years of age receiving up to salvage 3 therapy. A peripheral blood absolute blast count of < 20,000/μL was required for inclusion. LY2510924 was administered daily for 7 days followed by IA from day 8. Two dose escalation levels (10 and 20 mg) were evaluated, with a plan to enroll up to 12 patients in the phase I portion. Results: The median age of the enrolled patients (n = 11) was 55 years (range, 19–70). Median number of prior therapies was 1 (1–3). Six and five patients were treated at dose-levels "0" (10 mg) and "1" (20 mg), respectively. Only one patient experiencing a dose limiting toxicity (grade 3 rash and myelosuppression). Three and one complete responses were observed at dose-levels "0" and "1," respectively; the overall response rate (ORR) was 36% (4 of 11 patients). A ≥ 50% decrease in CXCR4 mean fluorescence intensity was observed in 4 of 9 patients by flow cytometry, indicating incomplete suppression of CXCR4-receptor occupancy. Conclusions: The combination of LY2510924 with IA is safe in R/R AML. Dose-escalation to a 30 mg LY2510924 dose is planned to achieve complete blockade of CXCR4 receptor occupancy, followed by expansion phase at the recommended phase 2 dose-level. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
20. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD--mutated, relapsed or refractory AML.
- Author
-
Cortes, Jorge E., Tallman, Martin S., Schiller, Gary J., Trone, Denise, Gammon, Guy, Goldberg, Stuart L., Perl, Alexander E., Marie, Jean-Pierre, Martinelli, Giovanni, Kantarjian, Hagop M., and Levis, Mark J.
- Subjects
- *
ACUTE myeloid leukemia , *GENETIC mutation , *KINASE inhibitors , *PROTEIN-tyrosine kinases , *MUTANT proteins , *DRUG dosage - Abstract
This randomized, open-label, phase 2b study (NCT01565668) evaluated the efficacy and safety of 2 dosing regimens of quizartinib monotherapy in patients with relapsed/ refractory (R/R) FLT3-internal tandem duplication (ITD)--mutated acute myeloid leukemia (AML) who previously underwent transplant or 1 second-line salvage therapy. Patients (N = 76) were randomly assigned to 30- or 60-mg/day doses (escalations to 60 or 90 mg/day, respectively, permitted for lack/loss of response) of single-agent oral quizartinib dihydrochloride. Allelic frequency of at least 10% was defined as FLT3-ITD--mutated disease. Coprimary endpoints were composite complete remission (CRc) rates and incidence of QT interval corrected by Fridericia's formula (QTcF) of more than 480 ms (grade 2 or greater). Secondary endpoints included overall survival (OS), duration of CRc, bridge to transplant, and safety. CRc rates were 47% in both groups, similar to earlier reports with higher quizartinib doses. Incidence of QTcF above 480 ms was 11% and 17%, and QTcF above 500 ms was 5% and 3% in the 30- and 60-mg groups, respectively, which is less than earlier reports with higher doses of quizartinib. Median OS (20.9 and 27.3weeks), duration of CRc (4.2 and 9.1 weeks), and bridge to transplant rates (32% and 42%) were higher in the 60-mg groups than in the 30-mg group. Dose escalation occurred in 61%and 14%of patients in the 30- and 60-mg groups, respectively. This high clinical activity of quizartinib at the evaluated doses is consistent with previous reports with an improved safety profile. Need to dose-escalate more than half of patients who received quizartinib 30mg also supports further investigation of treatment with quizartinib 60 mg/day. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
21. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia.
- Author
-
Abou Dalle, Iman, Cortes, Jorge E., Pinnamaneni, Pramod, Lamothe, Betty, Diaz Duque, Adolfo, Randhawa, Jasleen, Pemmaraju, Naveen, Jabbour, Elias, Ferrajoli, Alessandra, Wierda, William G., Estrov, Zeev, Konopleva, Marina, Ravandi, Farhad, Alvarado, Yesid, Borthakur, Gautam, Gandhi, Varsha, and Kantarjian, Hagop M.
- Subjects
- *
ERLOTINIB , *ACUTE myeloid leukemia treatment , *EPIDERMAL growth factor receptors , *DISEASE relapse , *DISEASE progression , *DRUG side effects , *DRUG efficacy - Abstract
Erlotinib, an epidermal growth factor receptor (EGFR) inhibitor, may have off-target activity inducing acute myeloid leukemia (AML) differentiation, possibly through SYK inhibition. We investigated erlotinib in a pilot phase II study for efficacy in relapsed/refractory AML patients at a dose of 150 mg once daily in 28-day cycles. Twenty-nine patients were treated for a median of 29 days (range 12–142 days). Seven patients (24%) received > 1 cycle of therapy and 12 (41%) discontinued treatment before day 28 due to disease progression. One patient (3%) achieved complete remission and 2 (7%) a > 50% reduction in blasts. The most common toxicities associated with erlotinib were fatigue in 10 patients (34%), diarrhea in 10 (34%), nausea in 8 (28%), and rash in 7 (24%). Only 2 patients (7%) had study drug-related adverse events requiring dose reductions and eventual discontinuation. The main reason for treatment discontinuation was disease progression in 26 patients (90%). All patients had died by the time of the last follow-up. Progression of disease was the primary cause of death in all patients. Median overall survival was 14 weeks (range 2.3–96.9 weeks) and median event-free survival was 5 weeks (range 1.7–21.0 weeks). Erlotinib as a single agent has limited clinical efficacy in patients with relapsed/refractory AML. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
22. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.
- Author
-
Kantarjian, Hagop M., DiNardo, Courtney D., Nogueras‐Gonzalez, Graciela M., Kadia, Tapan M., Jabbour, Elias, Bueso‐Ramos, Carlos E., O'Brien, Susan M., Konopleva, Marina, Jain, Nitin B., Daver, Naval G., Shpall, Elizabeth J., Champlin, Richard E., Simkins, Aron, Garcia‐Manero, Guillermo, Keating, Michael J., Huang, Xuelin, Cortes, Jorge E., Pierce, Sherry A., Ravandi, Farhad, and Freireich, Emil J.
- Subjects
ACUTE myeloid leukemia ,CYTARABINE ,PLATELET count ,CONFIDENCE intervals ,HEALTH outcome assessment - Abstract
Background: The prognosis is poor for patients who have relapsed-refractory acute myelogenous leukemia (AML). Most published reports analyzed results from therapies in first-salvage AML or in studies that were conducted before 2000. Several novel agents and strategies are being tested for potential approval as treatment for patients with relapsed-refractory AML in second salvage. Therefore, it is important to establish the historic results of anti-AML therapies in this setting in the modern era. The objective of the current study was to analyze the results from second salvage therapies in patients with AML since 2000 with regard to response and survival.Methods: In total, 673 patients who received second salvage therapies for AML since 2000 were analyzed. Their median age was 60 years (range, 18-89 years). Salvage therapy consisted of cytarabine-based regimens in 267 patients, noncytarabine combinations in 37, hypomethylating agent-based regimens in 136, and phase 1 and 2 single agents in 233.Results: Eighty-six of the 673 patients (13%) achieved a complete response (CR) or a CR with low platelet count (CRp). The median duration of CR-CRp was 7.2 months. The median survival was 4.4 months (95% confidence interval, 4.0-4.8 months), and the 1-year survival rate was 16% (95% confidence interval, 14%-19%). Multivariate analysis identified the following as independent adverse factors for achievement of CR-CRp: platelets < 50 × 109 /L (P < .001), complex karyotype with ≥3 chromosomal abnormalities (P = .02), regimens that did not include cytarabine or hypomethylating agents (P = .014), and no prior CR lasting ≥12 months with frontline or salvage 1 therapies (P < .001). The independent adverse factors associated with worse survival were age ≥60 years (P = .01), platelets < 50 × 109 /L (P = .02), peripheral blasts ≥ 20% (P = .03), albumin ≤ 3 g/dL (P = .04), and complex karyotype (P = .003). The authors also applied and validated, in the current population, the 2 multivariate-derived prognostic models for CR and survival developed in their previous study of 594 patients who received treatment for second salvage AML from the previous 2 decades.Conclusions: This large-scale analysis establishes the modern historic results of second salvage therapy in AML and validates the prognostic models associated with outcome. These data could be used to analyze the differential benefits of current or future investigational strategies under evaluation in this setting and for the purpose of potential approval of new agents in the United States and the world. Cancer 2018;124:2534-40. © 2018 American Cancer Society. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
23. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
- Author
-
Boddu, Prajwal Chaitanya, Kantarjian, Hagop M., Ravandi, Farhad, Garcia‐Manero, Guillermo, Verstovsek, Srdan, Jabbour, Elias J., Takahashi, Koichi, Bhalla, Kapil, Konopleva, Marina, DiNardo, Courtney D., Ohanian, Maro, Pemmaraju, Naveen, Jain, Nitin, Pierce, Sherry, Wierda, William G., Cortes, Jorge E., Kadia, Tapan M., and Garcia-Manero, Guillermo
- Subjects
OLDER patients ,ACUTE myeloid leukemia treatment ,BLOOD diseases ,MYELODYSPLASTIC syndromes ,CYTARABINE ,ANTINEOPLASTIC agents ,CHROMOSOMES ,MULTIVARIATE analysis ,LOGISTIC regression analysis ,ACUTE myeloid leukemia ,TREATMENT effectiveness ,DISEASE remission ,PROPORTIONAL hazards models ,RETROSPECTIVE studies ,AZACITIDINE ,SECONDARY primary cancer ,THERAPEUTICS - Abstract
Background: The development of newer strategies to improve outcomes for older patients with secondary acute myeloid leukemia (s-AML) is a critical unmet need. Establishing baseline metrics for evaluating newer approaches is important.Methods: s-AML was defined as 1 or more of the following: a history of an antecedent hematologic disorder (AHD), a diagnosis of therapy-related acute myeloid leukemia (AML), and AML with karyotype abnormalities characteristic of myelodysplastic syndrome. Newly diagnosed s-AML patients aged 60 to 75 years were grouped into 5 treatment cohorts: 1) patients receiving high- or intermediate-dose cytarabine-based intensive chemotherapy (IC), 2) patients receiving a hypomethylating agent (HMA) or HMA combinations, 3) patients receiving low-dose cytarabine (LDAC) combinations, 4) patients receiving CPX-351, and 5) patients receiving investigational (INV) agents. Nine hundred thirty-one patients met the age and s-AML criteria.Results: Complete remission rates were statistically lower in the HMA group (36%) versus the IC (46%), CPX-351 (45%), and LDAC groups (43%). Patients receiving less intensive regimens (the HMA and LDAC groups combined) had superior overall survival (OS) in comparison with patients receiving IC-based regimens (median 6.9 vs 5.4 months; P = .048). Only 4.3% of the IC patients proceeded to transplantation, whereas 10.3% of the patients on lower intensity regimens did (P = .001). There was no difference in median survival between patients treated with CPX-351 and patients treated with conventional lower intensity approaches (P = .75). Age > 70 years, an adverse karyotype, and a prior AHD were associated with decreased OS in a multivariate analysis.Conclusions: Lower intensity approaches are associated with lower early mortality rates and improved OS in comparison with intensive regimens. OS is poor with currently available therapies with a median OS of 6 months (5.4-7.6 months across regimens). Unsatisfactory outcomes with other INV agents underscore the need for more effective therapies. Cancer 2017;123:3050-60. © 2017 American Cancer Society. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
24. Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
- Author
-
Bose, Prithviraj, Vachhani, Pankit, Cortes, Jorge, and Cortes, Jorge E
- Subjects
ACUTE myeloid leukemia treatment ,ANTINEOPLASTIC agents ,DRUG therapy ,CLINICAL trials ,COMBINED modality therapy ,DRUG resistance in cancer cells ,IMMUNOTHERAPY ,REOPERATION ,RESEARCH funding ,DISEASE relapse ,ACUTE myeloid leukemia ,TREATMENT effectiveness - Abstract
Opinion Statement: Approximately 40-45% of younger and 10-20% of older adults with acute myeloid leukemia (AML) will be cured with current standard chemotherapy. The outlook is particularly gloomy for patients with relapsed and/or refractory disease (cure rates no higher than 10%). Allogeneic hematopoietic stem cell transplantation (HSCT), the only realistic hope of cure for these patients, is an option for only a minority. In recent years, much has been learned about the genomic and epigenomic landscapes of AML, and the clonal architecture of both de novo and secondary AML has begun to be unraveled. These advances have paved the way for rational drug development as new "drugable" targets have emerged. Although no new drug has been approved for AML in over four decades, with the exception of gemtuzumab ozogamycin, which was subsequently withdrawn, there is progress on the horizon with the possible regulatory approval soon of agents such as CPX-351 and midostaurin, the Food and Drug Administration "breakthrough" designation granted to venetoclax, and promising agents such as the IDH inhibitors AG-221 and AG-120, the smoothened inhibitor glasdegib and the histone deacetylase inhibitor pracinostat. In our practice, we treat most patients with relapsed/refractory AML on clinical trials, taking into consideration their prior treatment history and response to the same. We utilize targeted sequencing of genes frequently mutated in AML to identify "actionable" mutations, e.g., in FLT3 or IDH1/2, and incorporate small-molecule inhibitors of these oncogenic kinases into our therapeutic regimens whenever possible. In the absence of actionable mutations, we rationally combine conventional agents with other novel therapies such as monoclonal antibodies and other targeted drugs. For fit patients up to the age of 65, we often use high-dose cytarabine-containing backbone regimens. For older or unfit patients, we prefer hypomethylating agent-based therapy. Finally, all patients with relapsed/refractory AML are evaluated for allogeneic HSCT. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
25. Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia.
- Author
-
Chen, Lisa S., Yang, Ji-Yeon, Liang, Han, Cortes, Jorge E., and Gandhi, Varsha
- Subjects
MTOR protein ,ACUTE myeloid leukemia ,CELL lines ,IMMUNOBLOTTING ,PROTEIN synthesis ,KINASE inhibitors - Abstract
Pim kinases phosphorylate and regulate a number of key acute myeloid leukemia (AML) cell survival proteins, and Pim inhibitors have recently entered clinical trial for hematological malignancies. AZD1208 is a small molecule pan-Pim kinase inhibitor and AZD1208 treatment resulted in growth inhibition and cell size reduction in AML cell lines including FLT3-WT (OCI-AML-3, KG-1a, and MOLM-16) and FLT3-ITD mutated (MOLM-13 and MV-4-11). There was limited apoptosis induction (<10% increase) in the AML cell lines evaluated with up to 3 μM AZD1208 for 24 h, suggesting that growth inhibition is not through apoptosis induction. Using reverse phase protein array (RPPA) and immunoblot analysis, we identified that AZD1208 resulted in suppression of mTOR signaling, including inhibition of protein phosphorylation of mTOR (Ser2448), p70S6K (Thr389), S6 (Ser235/236), and 4E-BP1 (Ser65). Consistent with mTOR inhibition, there was also a reduction in protein synthesis that correlated with cell size reduction and growth inhibition with AZD1208; our study provides insights into the mechanism of AZD1208. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
26. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors.
- Author
-
Wei Wang, Cortes, Jorge E., Pei Lin, Beaty, Michael W., Di Ai, Amin, Hesham M., McDonnell, Timothy J., Chi Young Ok, Kantarjian, Hagop M., Medeiros, L. Jeffrey, and Shimin Hu
- Subjects
- *
CHROMOSOME abnormalities , *TREATMENT of chronic myeloid leukemia , *PROTEIN-tyrosine kinase inhibitors , *DISEASE prevalence , *ACUTE myeloid leukemia - Abstract
Chromosome 3q26.2 abnormalities in acute myeloid leukemia, including inv(3)/t(3;3) and t(3;21), have been studied and are associated with a poor prognosis. Their prevalence, response to tyrosine kinase inhibitor (TKI) treatment, and prognostic significance in chronic myelogenous leukemia (CML) are largely unknown. In this study, we explored these aspects using a cohort of 2013 patients with CML diagnosed in the era of TKI therapy. Chromosome 3 abnormalities were observed in 116 (5.8%) of 2013 cases. These cases were divided into 5 distinct groups: A, inv(3)(q21q26.2)/t(3;3)(q21;q26.2), 26%; B, t(3;21)(q26.2;q22), 17%; C, other 3q26.2 rearrangements, 7%; D, rearrangements involving chromosome 3 other than 3q26.2 locus, 32%; and E, gain or loss of partial or whole chromosome3, 18%. In all, 3q26.2 rearrangements were the most common chromosome 3 abnormalities (50%, groups A-C). 3q26.2 rearrangements emerged at different leukemic phases. For cases with 3q26.2 rearrangements that initially emerged in chronic or accelerated phase, they had a high rate of transformation to blast phase. Patients with 3q26.2 abnormalities showed a marginal response to TKI treatment, and no patients achieved a long-term sustainable response at a cytogenetic or molecular level. Compared with other chromosomal abnormalities in CML, patients with 3q26.2 rearrangements had poorer overall survival. The presence or absence of other concurrent chromosomal abnormalities did not affect survival in these patients, reflecting the predominant role of 3q26.2 rearrangements in determining prognosis. Interestingly, although heterogeneous, chromosome 3 abnormalities involving non-3q26.2 loci (groups D, E) also conferred a worse prognosis compared with changes involving other chromosomes in this cohort. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
27. SY31-1 Molecular targeted therapy with FLT3 inhibitor in AML.
- Author
-
Cortes, Jorge E.
- Subjects
- *
ACUTE myeloid leukemia - Published
- 2022
- Full Text
- View/download PDF
28. Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
- Author
-
Heuser, Michael, Smith, B. Douglas, Fiedler, Walter, Sekeres, Mikkael A., Montesinos, Pau, Leber, Brian, Merchant, Akil, Papayannidis, Cristina, Pérez-Simón, José A., Hoang, Caroline J., O'Brien, Thomas, Ma, Weidong Wendy, Zeremski, Mirjana, O'Connell, Ashleigh, Chan, Geoffrey, and Cortes, Jorge E.
- Subjects
ACUTE myeloid leukemia ,CYTARABINE - Abstract
A correction to this paper has been published: https://doi.org/10.1007/s00277-021-04545-5 [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
29. The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes.
- Author
-
Jabbour, Elias, Garcia-Manero, Guillermo, Cornelison, A. Megan, Cortes, Jorge E., Ravandi, Farhad, Daver, Naval, Kadia, Tapan, Teng, Angela, and Kantarjian, Hagop
- Subjects
MYELODYSPLASTIC syndromes treatment ,DECITABINE ,DRUG dosage ,ACUTE myeloid leukemia ,DISEASE progression - Abstract
Myelosuppression in myelodysplastic syndromes (MDS) is associated with the hypomethylating agent decitabine. A retrospective pooled analysis of two decitabine clinical trials in patients with MDS conducted Cox regression analyses of red blood cell or platelet dependence, myelosuppression, dose modification, cycle delay or dose reduction, and survival effects. In 182 patients, baseline platelet dependence was a predictor for dose modification, reduction or delay, and death (modification: p = 0.006, hazard ratio [HR] = 2.04; reduction/delay: p = 0.011, HR = 2.00; death: p = 0.003, HR = 1.94). Patients with dose modifications had significantly higher overall response rates versus those with none (22% vs. 10%; p = 0.015). Patients with no dose modifications had faster progression to acute myeloid leukemia (AML) versus patients with dose modifications ( p = 0.004). Without dose modifications, patients tended to drop out due to disease progression or other reasons. Decitabine dose modifications on treatment may indicate response to treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
30. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
- Author
-
Alvarado, Yesid, Kantarjian, Hagop M., Luthra, Rajyalakshmi, Ravandi, Farhad, Borthakur, Gautam, Garcia‐Manero, Guillermo, Konopleva, Marina, Estrov, Zeev, Andreeff, Michael, and Cortes, Jorge E.
- Subjects
ACUTE myeloid leukemia treatment ,PROTEIN-tyrosine kinases ,GENETIC mutation ,KINASE inhibitors - Abstract
BACKGROUND FLT3-internal tandem duplication (ITD) mutations are found in approximately 30% of patients with acute myeloid leukemia (AML). FLT3 inhibitors have shown clinical activity in AML with FLT3-ITD, but responses are usually short-lived. METHODS This study examined 69 FLT3-mutated patients with AML, who were treated with different FLT3 inhibitors to analyze emergence of new mutations. RESULTS At baseline, 87% of patients had an ITD mutation, 7% had a D835/I836 mutation, and 6% had combined ITD and D835/I836 mutations. Responses occurred in 32% of patients, all with FLT3-ITD; none of the patients with D835/I836 or ITD+D835/I836 responded. Mutational assessment at the time of FLT3 inhibitor discontinuation showed that 68% of patients were unchanged, 10% had become undetectable, and 22% of patients progressed from a single ITD to have combined ITD+D835/I836 mutations. In those patients with unchanged FLT3 mutation at progression, the median survival was 5 months, whereas in those with undetectable and with combined ITD+D835/I836 mutations, the median survival was 7 months, respectively. CONCLUSIONS These data confirm in vitro observations that a secondary tyrosine kinase domain mutation may arise after the use of FLT3 inhibitors in patients with single FLT3-ITD mutated AML, a phenomenon that is associated with resistance and a poor prognosis. Cancer 2014;120:2142-2149. © 2014 American Cancer Society. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
31. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.
- Author
-
Lancet, Jeffrey E., Cortes, Jorge E., Hogge, Donna E., Tallman, Martin S., Kovacsovics, Tibor J., Damon, Lloyd E., Komrokji, Rami, Solomon, Scott R., Kolitz, Jonathan E., Cooper, Maureen, Yeager, Andrew M., Louie, Arthur C., and Feldman, Eric J.
- Subjects
- *
CYTARABINE , *DAUNOMYCIN , *ACUTE myeloid leukemia , *DISEASE remission , *NEUTROPHILS , *CLINICAL trials , *DRUG efficacy , *PATIENTS - Abstract
CPX-351 is a liposomal formulation of cytarabine:daunorubicin designed to deliver synergistic drug ratios to leukemia cells, in this phase 2 study, newly diagnosed older acute myeloid leukemia (AML) patients were randomized 2:1 to first-line CPX-351 or 7+3 treatment. The goal was to determine efficacy and identify patient subgroups that may benefit from CPX-351 treatment. Response rate (complete remission + Incomplete remission) was the primary end point, with event-free survival (EFS) and overall survival (OS) as secondary end points. The 126 patients entered were balanced for disease and patient-specific risk factors. Overall, CPX-351 produced higher response rates (66.7% vs 51.2%, P = .07), meeting predefined criteria for success (P< .1 ). Differences in EFS and OS were not statistically significant. A planned analysis of the secondary AML subgroup demonstrated an improved response rate (57.6% vs 31.6%, P = .06), and prolongation of EFS (hazard ratio [HR] = 0.59, P = .08) and OS (HR = 0.46, P = .01). Recovery from cytopenias was slower after CPX-351 (median days to absolute neutrophil count ≥1000:36 vs 32; platelets >100 000:37 vs 28) with more grade 3-4 infections but without increase in infection-related deaths (3.5% vs 7.3%) or 60-day mortality (4.7% vs 14.6%), indicating acceptable safety. These results suggest a clinical benefit with CPX-351, particularly among patients with secondary AML, and provide the rationale for a phase 3 trial currently underway in newly diagnosed secondary AML patients. This study is registered at Clinical trials. gov as #NCT00788892. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
32. CD105 (Endoglin) Is Highly Overexpressed in a Subset of Cases of Acute Myeloid Leukemias.
- Author
-
Chakhachiro, Zaher I., Zuo, Zhuang, Aladily, Tariq N., Kantarjian, Hagop M., Cortes, Jorge E., Alayed, Khaled, Nguyen, Martin H., Medeiros, L. Jeffrey, and Bueso-Ramos, Carlos
- Subjects
ENDOGLIN ,ACUTE myeloid leukemia ,IMMUNOHISTOCHEMISTRY ,BONE marrow ,BIOLOGICAL specimens - Abstract
Objectives: To assess CD105 (endoglin) expression in 119 acute myeloid leukemia (AML) and 13 control cases using immunohistochemistry. Methods: CD105 expression was assessed retrospectively by using immunohistochemistry in bone marrow specimens. Results: CD105 was strongly and diffusely positive in all 9 (100%) AMLs with t(15;17)(q24.1;q21.2), 2 (100%) AMLs with t(8;21)(q22;q22), 1 (100%) AML with t(6;9)(p23;q34), 7 (28%) of 25 AMLs with myelodysplasia-related changes, 1 (33%) of 3 therapy-related AMLs, 3 (16%) of 19 AMLs unclassifiable, 1 (14%) of 7 AMLs with inv(16)(p13.1q22), and 5 (11%) of 45 AMLs not otherwise specified. Uninvolved bone marrow in these cases showed no CD105 expression by erythroid precursors, megakaryocytes, or endothelial or stromal cells. Two of 13 control bone marrow specimens showed partial CD105 positivity in myeloid cells. In 21 strongly CD105+ AML cases tested for the IDH2 mutation, 9 (42%) were mutated (P = .004). Conclusions: These data suggest that CD105 could be a therapeutic target in a subset of patients with AML. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
33. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia.
- Author
-
Santos, Fabio P. S., Jones, Dan, Wei Qiao, Cortes, Jorge E., Ravandi, Farhad, Estey, Elihu E., Verma, Dushyant, Kantarjian, Hagop, and Borthakur, Gautam
- Subjects
PROGNOSIS ,PROTEIN-tyrosine kinases ,TYROSINE ,MUTAGENESIS ,ACUTE myeloid leukemia - Abstract
The article evaluates the prognostic impact on survival of FMS-like tyrosine kinase 3 (FLT3) mutations in well defined cytogenetic subgroups of patients with acute myeloid leukemia (AML). Patients with normal karyotype-AML (NK-AML) and higher FLT3-internal tandem duplication (ITD) showed worse event-free survival (EFS) and overall survival (OS). The researchers concluded that FLT3 mutations have no impact in patients with AML who had good-risk and poor-risk karyotypes.
- Published
- 2011
- Full Text
- View/download PDF
34. Daily Palonosetron Is Superior to Ondansetron in the Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting in Patients With Acute Myelogenous Leukemia.
- Author
-
Mattiuzzi, Gloria N., Cortes, Jorge E., Blamble, Deborah A., Bekele, B. Nebiyou, Lianchun Xiao, Cabanillas, Maria, Borthakur, Gautam, O'Brien, Susan, and Kantarjian, Hagop
- Subjects
- *
DRUG therapy , *DRUG side effects , *NAUSEA , *VOMITING , *ACUTE myeloid leukemia , *ONDANSETRON - Abstract
This article discusses a study which compared two schedules of palonosetron versus ondansetron in the treatment of chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia (AML) receiving cytarabine. The study included 47 patients on ondansetron and 48 patients on each of the palonosetron. It revealed that the daily assessments of emesis did not show significant differences between the study arms.
- Published
- 2010
- Full Text
- View/download PDF
35. Survival Is Poorer in Patients With Secondary Core-binding Factor Acute Myelogenous Leukemia Compared With De Novo Core-binding Factor Leukemia.
- Author
-
Borthakur, Gautam, Lin, E., Jain, Nitin, Estey, Elihu E., Cortes, Jorge E., O'Brien, Susan, Faderl, Stefan, Ravandi, Farhad, Pierce, Sherry, and Kantarjian, Hagop
- Subjects
CLINICAL trials ,LEUKEMIA ,ACUTE leukemia ,ACUTE myeloid leukemia ,MULTIVARIATE analysis ,SURVIVAL analysis (Biometry) - Abstract
The article presents a study which compares the overall survival (OS) rate to patients with secondary core-binding factor acute myelogenous leukemia (CBF AML) compared to patients with de novo CBF AML. Result shows that patients with secondary CBF AML were found to have worse overall (OS) compared to patients with de novo CBF AML. The secondary CBF AML status appeared to have marginal significance in multivariate analysis that indicates worse OS and event-free survival (EFS).
- Published
- 2009
- Full Text
- View/download PDF
36. A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia
- Author
-
Giles, Francis J., Cortes, Jorge E., Kantarjian, Hagop M., O’Brien, Susan M., Estey, Elihu, and Beran, Miloslav
- Subjects
- *
ACUTE myeloid leukemia , *FLUDARABINE , *PATIENTS , *RESEARCH - Abstract
As fludarabine, topotecan and cytarabine (ara-C) are effective in acute myeloid leukemia (AML), a pilot study of these three agents combined (FTA) was conducted. FTA consisted of topotecan 1.25 mg/m2 by CIV days 1–5, fludarabine 15 mg/m2 and ara-C 0.5 g/m2 IV, BID, on days 2–6. Seventeen patients (6 primary resistant, 11 relapsed) with AML received 33 courses of FTA. Six patients (35%) achieved complete remission. Seven patients (41%) developed grade 3 or 4 diarrhea. FTA was effective and warrants further study in patients with refractory AML. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
37. Clinical Outcomes and Characteristics of Patients (pts) with FLT3–Internal Tandem Duplication (FLT3-ITD)–Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial
- Author
-
Ganguly, Siddhartha, Cortes, Jorge E., Krämer, Alwin, Levis, Mark J., Martinelli, Giovanni, Perl, Alexander E., Russell, Nigel H., Arunachalam, Meena, Gammon, Guy, Lesegretain, Arnaud, Mires, Derek E., and Khaled, Samer K.
- Subjects
- *
STEM cell transplantation , *HEMATOPOIETIC stem cells , *ACUTE myeloid leukemia , *HEMATOPOIETIC stem cell transplantation , *CANCER chemotherapy - Abstract
In QuANTUM-R, the once-daily, oral, highly potent and selective FLT3 inhibitor Q improved clinical benefit vs SC (median overall survival [mOS], 6.2 vs 4.7 mo [HR, 0.76 (95% CI, 0.58-0.98); P =.02]) in R/R FLT3 -ITD AML (NCT02039726). Before randomization, 25% (Q) and 23% (SC) of pts had 1 prior HSCT. To describe post hoc analyses in pts who underwent subsequent HSCT during QuANTUM-R. Pts with FLT3 -ITD R/R AML received Q (60 mg [30-mg lead-in]) or SC. Pts in the Q arm could resume Q 30-100 d after HSCT. Decisions to proceed to HSCT and resume Q after HSCT were made per investigator discretion/institutional policy. Of 367 randomized pts, 85 in the Q arm underwent any subsequent HSCT (allogeneic HSCT [allo-HSCT], 84 [6 with and 78 w/o additional AML therapy]; autologous HSCT, 1), and 19 in the SC arm underwent any HSCT (5 with and 14 w/o additional AML therapy]). Q + SC pooled data showed a longer mOS (95% CI) in 104 pts with any HSCT vs 263 w/o (12.2 [10.0-24.1] vs 4.4 [4.1-4.9] mo; P <.0001; Fig 1); 1-year OS rates were 50% vs 13%. Among pts preselected for low-intensity therapy, 13/57 in the Q arm and 0/29 in the SC arm underwent any HSCT. Q + SC pooled data also showed a longer mOS (95% CI) in pts with a composite complete remission (CRc) as last recorded response before allo-HSCT vs pts w/o CRc (20.1 [11.7-NA] vs 8.8 [7.0-11.4] mo). Regardless of treatment, mOS was longer with any HSCT vs w/o (Q, 11.9 [10.2-25.1] vs 4.5 [4.1-5.4] mo; SC, 12.7 [6.1-NA] vs 4.0 [2.7-5.0] mo); respective 1-year OS rates were 50% vs 13% and 51% vs 12%. In the Q arm, mOS (95% CI) was longer in pts with a best response of CRc who resumed Q after allo-HSCT (27.1 [18.2-NA] mo) vs pts not resuming Q (5.4 [4.7-11.4] mo; Fig 2). In 48 pts (62%) in the Q arm resuming Q after allo-HSCT, median time from allo-HSCT to Q resumption was 65 d (range, 30-106 d). Four pts (5%) in the Q arm died < 30 d after allo-HSCT. As of 2/22/2018, 46/78 pts in the Q arm (59%) and 9/14 pts in the SC arm (64%) with allo-HSCT w/o additional AML therapy died, mostly due to AML progression (Q, 31 [40%]; SC, 7 [50%]). The frequency of treatment-emergent adverse events (TEAEs) and TEAEs of interest was similar in pts resuming Q after allo-HSCT and in the overall Q population. Independent of HSCT, Q improved survival vs SC in pts with FLT3 -ITD R/R AML in QuANTUM-R. Q + SC pooled analyses showed longer survival in pts with HSCT vs pts w/o and in pts with CRc before allo-HSCT. Survival in transplanted pts was similar in both arms, indicating that HSCT-eligible pts received transplants appropriately, and the higher HSCT rate in the Q arm was beneficial. In pts preselected for low-intensity SC at study entry, 13 were able to undergo HSCT after Q treatment. Q resumption after HSCT was associated with better survival outcomes and was tolerable. These data illustrate the value of using Q to target the FLT3 -ITD mutation as a part of the overall treatment sequence in pts with FLT3 -ITD R/R AML. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
38. PS2-3 [Encore] Quizartinib in FLT3-ITD-Mutated Relapsed/Refractory Acute Myeloid Leukemia: QuANTUM-R Trial Results.
- Author
-
Cortes, Jorge E, Khaled, Samer, Martinelli, Giovanni, Perl, Alexander E, Ganguly, Siddhartha, Russell, Nigel H, Kramer, Alwin, Dombret, Herve, Hogge, Donna, Jonas, Brian A, Leung, Anskar Yh, Mehta, Priyanka, Montesinos, Pau, Radsak, Markus P, Sica, Simona, Arunachalam, Meena, Holmes, Melissa, Namuyinga, Ruth, Zhang, Yufen, and Levis, Mark J
- Subjects
- *
ACUTE myeloid leukemia , *STEM cell transplantation , *HEMATOPOIETIC stem cells , *HEMATOPOIETIC stem cell transplantation - Abstract
Background FLT3-ITD mutations occur in about 25% of patients (pts) with acute myeloid leukemia (AML) and are associated with poor outcomes. Pts with relapsed/refractory (R/R) FLT3-ITD AML have worse prognosis and high unmet medical need. Quizartinib (Q) is a potent and selective FLT3i with promising activity and a manageable safety profile. QuANTUM-R was a global, phase 3, randomized trial of Q vs chemotherapy (SC) in pts with R/R FLT3-ITD AML (NCT02039726). Methods Pts with R/R FLT3-ITD AML w/wo hematopoietic stem cell transplant (HSCT) were randomized to receive Q or a preselected investigator choice SC: low-dose cytarabine; mitoxantrone, etoposide, and intermediate-dose cytarabine (MEC); or fludarabine, cytarabine, and G-CSF with idarubicin (FLAG-IDA). Prior midostaurin was allowed. Pts receiving HSCT after Q could resume Q after HSCT. Primary and secondary endpoints were overall survival (OS) and event-free survival (EFS), respectively. Exploratory endpoints included response rate, time to and duration of response, and transplant rate. Results 367 pts were randomized; 245 to Q and 122 to SC. Median follow-up was 23.5 mo. OS hazard ratio (HR) of Q relative to SC was 0.76 (95% CI, 0.58-0.98; P=.0177). Median OS was 6.2 (95% CI, 5.3-7.2) vs 4.7 (95% CI, 4.0-5.5) mo in Q and SC arms, respectively. EFS HR was 0.90 (95% CI, 0.70-1.16; P=.1071); median EFS was 1.4 (95% CI, 0.0-1.9) vs 0.9 (95% CI, 0.4-1.3) mo, respectively. Sensitivity analyses and OS subgroup analyses supported Q vs SC. Composite complete response (CRc) was 48% and 27% in Q and SC arms, respectively. Transplant rate was 32% (Q) and 12% (SC). Median time to first CRc was 4.9 wk for Q. The most common grade ≥ 3 TEAEs in both arms were infections and those associated with cytopenia. Conclusion OS benefit was observed with single-agent Q vs SC in pts with R/R FLT3-ITD AML with a favorable Q safety profile, providing evidence of meaningful clinical benefit in pts with limited treatment options. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
39. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes
- Author
-
Giles, Francis J., Kantarjian, Hagop M., Cortes, Jorge E., Faderl, Stephan, Verstovsek, Srdan, Thomas, Deborah, Garcia-Manero, Guillermo, Wierda, William, Ferrajoli, Alessandra, Kornblau, Stephen, Mattiuzzi, Gloria N., Tsimberidou, Apostolia M., Albitar, Maher, O’Brien, Susan M., and Estey, Elihu
- Subjects
- *
MYELOID leukemia , *BRADYCARDIA , *MYELODYSPLASTIC syndromes , *BONE marrow diseases - Abstract
Abstract: A higher complete remission (CR) rate was observed in patients with acute myeloid leukemia (AML) who, on a prior randomized study of induction therapy, received gemtuzumab ozogamicin (GO) plus interleukin-11 (IL-11) rather than GO alone. An adaptive randomized phase III study of the addition of IL-11 to idarubicin and cytarabine (IA) induction in 100 patients ≥50 years of age with AML or high-risk myelodysplastic syndrome (MDS) was conducted. Median patient age was 67 years (range 50–82). Twenty-four of the 45 (53%) patients randomized to IA plus IL-11 achieved CR. Eight (33%) subsequently relapsed, 4 (17%) died in CR; median time to treatment failure (TTF) was 37 weeks. Twenty-nine of the 55 (53%) patients treated without IL-11 achieved CR. Eight (28%) subsequently relapsed, 2 (7%) died in CR; median TTF was 46 weeks. Median overall survivals were 21 and 59 weeks for the IA plus IL-11 and IA cohorts, respectively (p =0.271, log rank test; 0.435, Gehan–Breslow test). Ten episodes of the following grade 3 or 4 cardiopulmonary toxicities were observed in patients receiving IA plus IL-11, 12 such episodes in those receiving IA alone: atrial fibrillation, pleural effusions, myocardial infarction, bradycardia or hypotension. Two patients in each arm experienced grade 3 peripheral edema. There was no significant difference in incidence of any grade 3 or 4 adverse event, including thrombocytopenia, between treatment arms. There was no significant impact on CR rates, TTF, survival, or toxicity of adding an IL-11 regimen to IA induction in patients ≥50 years of age with AML. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
40. KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.
- Author
-
Swords, Ronan T., Greenberg, Peter L., Wei, Andrew H., Durrant, Simon, Advani, Anjali S., Hertzberg, Mark S., Lewis, Ian D., Rivera, Gabriel, Gratzinger, Dita, Fan, Alice C., Felsher, Dean W., Cortes, Jorge E., Watts, Justin M., Yarranton, Geoff T., Walling, Jackie M., and Lancet, Jeffrey E.
- Subjects
- *
HEMATOLOGIC malignancies , *THERAPEUTIC use of monoclonal antibodies , *TARGETED drug delivery , *PROTEIN-tyrosine kinases , *GENETIC overexpression , *PHARMACODYNAMICS , *PHARMACOKINETICS , *THERAPEUTICS - Abstract
EphA3 is an Ephrin receptor tyrosine kinase that is overexpressed in most hematologic malignancies. We performed a first-in-human multicenter phase I study of the anti-EphA3 monoclonal antibody KB004 in refractory hematologic malignancies in order to determine safety and tolerability, along with the secondary objectives of pharmacokinetics (PK) and pharmacodynamics (PD) assessments, as well as preliminary assessment of efficacy. Patients were enrolled on a dose escalation phase (DEP) initially, followed by a cohort expansion phase (CEP). KB004 was administered by intravenous infusion on days 1, 8, and 15 of each 21-day cycle in escalating doses. A total of 50 patients (AML 39, MDS/MPN 3, MDS 4, DLBCL 1, MF 3) received KB004 in the DEP; an additional 14 patients were treated on the CEP (AML 8, MDS 6). The most common toxicities were transient grade 1 and grade 2 infusion reactions (IRs) in 79% of patients. IRs were dose limiting above 250 mg. Sustained exposure exceeding the predicted effective concentration (1ug/mL) and covering the 7-day interval between doses was achieved above 190 mg. Responses were observed in patients with AML, MF, MDS/MPN and MDS. In this study, KB004 was well tolerated and clinically active when given as a weekly infusion. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
41. Acute myeloid leukaemia.
- Author
-
Rushton, Jonathan, Bruce, Mieghan, Bellet, Camille, Torgerson, Paul, Shaw, Alexandra, Marsh, Tom, Pigott, David, Stone, Matthew, Pinto, Julio, Mesenhowski, Shannon, Wood, Paul, Short, Nicholas J, Rytting, Michael E, and Cortes, Jorge E
- Subjects
- *
ANIMAL diseases , *DISEASE risk factors , *DECISION making , *INFECTION , *MORTALITY , *ACUTE myeloid leukemia treatment , *AMINOGLYCOSIDES , *ANTINEOPLASTIC agents , *THERAPEUTIC use of monoclonal antibodies , *ACUTE myeloid leukemia diagnosis , *ALKALOIDS , *DRUG therapy , *HEMATOPOIETIC stem cell transplantation , *RISK assessment , *DISEASE relapse , *GENOMICS , *ACUTE myeloid leukemia , *DISEASE remission , *PATIENT selection , *CYTARABINE , *THERAPEUTICS ,THERAPEUTIC use of alkaloids - Abstract
For several decades, few substantial therapeutic advances have been made for patients with acute myeloid leukaemia. However, since 2017 unprecedented growth has been seen in the number of drugs available for the treatment of acute myeloid leukaemia, with several new drugs receiving regulatory approval. In addition to advancing our therapeutic armamentarium, an increased understanding of the biology and genomic architecture of acute myeloid leukaemia has led to refined risk assessment of this disease, with consensus risk stratification guidelines now incorporating a growing number of recurrent molecular aberrations that aid in the selection of risk-adapted management strategies. Despite this promising recent progress, the outcomes of patients with acute myeloid leukaemia remain unsatisfactory, with more than half of patients ultimately dying from their disease. Enrolment of patients into clinical trials that evaluate novel drugs and rational combination therapies is imperative to continuing this progress and further improving the outcomes of patients with acute myeloid leukaemia. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
42. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.
- Author
-
Badar, Talha, Kantarjian, Hagop M., Ravandi, Farhad, Jabbour, Elias, Borthakur, Gautam, Cortes, Jorge E., Pemmaraju, Naveen, Pierce, Sherry R., Newberry, Kate J., Daver, Naval, and Verstovsek, Srdan
- Subjects
- *
DECITABINE , *MYELOFIBROSIS , *MYELOPROLIFERATIVE neoplasms , *ACUTE myeloid leukemia , *ACUTE myeloid leukemia treatment , *PATIENTS , *THERAPEUTICS - Abstract
Myeloproliferative neoplasm (MPN) transformed to acute myeloid leukemia (MPN-AML), MPN in accelerated phase (MPN-AP), and high-risk primary myelofibrosis (PMF) are associated with a poor response to therapy and very short survival. Several reports have suggested clinical activity of hypomethylating agents in these patients. We conducted a retrospective study of 21 patients with MPN-AML, 13 with MPN-AP and 11 with DIPSS-plus high-risk PMF treated with decitabine at our institution over the last 7 years and evaluated their clinical outcomes. Six patients (29%) with MPN-AML responded to decitabine (3 CR, 2 CRi, and 1 PR); median response duration was 7 months. The median overall survival (OS) was significantly higher in those who responded (10.5 vs 4 months). Among patients with MPN-AP, 8 patients (62%) benefited; the median response duration was 6.5 months. The median OS was 11.8 months in responders vs 4.7 months in non-responders. Among patients with DIPSS-plus high-risk PMF, 9 (82%) benefited; the median response duration was 9 months. The median OS was 32 months in responders vs 16.3 months in non-responders. Decitabine is a viable therapeutic option for patients with MPN-AML, MP-AP and high-risk PMF. Prospective clinical studies combining decitabine with other clinically active agents are needed to improve overall outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
43. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia.
- Author
-
Chen, Lisa S., Redkar, Sanjeev, Taverna, Pietro, Cortes, Jorge E., and Gandhi, Varsha
- Subjects
- *
ACUTE myeloid leukemia , *CELL-mediated cytotoxicity , *APOPTOSIS , *PYRIDAZINES , *PHOSPHORYLATION - Abstract
Pim kinases are Ser/Thr kinases with multiple substrates that affect survival pathways. These proteins are overexpressed in acute myeloid leukemia (AML) blasts and we hypothesized that Pim kinase inhibition would affect AML cell survival. Imidazo[1,2-b]pyridazine compound, SGI-1776 inhibits Pim-1, Pim-2 and Pim-3, and was evaluated in AML-cell line, -xenograft model, and -primary blasts. Treatment of AML cells with SGI-1776 results in a concentration-dependent induction of apoptosis and we investigated its effect on Pim kinase functions. Phosphorylation of traditional Pim kinase targets, c-Myc(Ser62) and 4E-BP1 (Thr36/Thr47), were both decreased in actively cycling AML cell lines MV-4-11, MOLM-13 and OCI-AML-3. Levels of antiapoptotic proteins Bcl-2, Bcl-xL, XIAP, and proapoptotic Bak and Bax were unchanged; however, a significant reduction in Mcl-1 was observed. This was correlated with inhibition of global RNA and protein synthesis and MCL-1 transcript decline after SGI-1776 treatment. These data suggest that SGI-1776 mechanism in AML involves Mcl-1 protein reduction. Consistent with cell line data, xenograft model studies with mice bearing MV-4-11 tumors showed efficacy with SGI-1776. Importantly, SGI-1776 was also cytotoxic in AML primary cells, irrespective of FLT3 mutation status and resulted in Mcl-1 protein decline. Pim kinase inhibition may be a new strategy for AML treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
44. Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis.
- Author
-
Rizzieri, David A, Schiller, Gary J., Solomon, Scott R., Newell, Laura F., Erba, Harry P., Ryan, Robert J., Faderl, Stefan, Cortes, Jorge E., and Lancet, Jeffrey E.
- Subjects
- *
ACUTE myeloid leukemia , *LIPOSOMES , *SUMATRIPTAN , *PACLITAXEL , *CELL transplantation , *RADIOTHERAPY , *ODDS ratio - Abstract
t-AML arises from prior cytotoxic therapy, ionizing radiotherapy, or immunosuppressive therapy for an unrelated disease and is associated with poorer outcomes relative to de novo AML, with a median overall survival (OS) of ∼6 mo following conventional chemotherapy. CPX-351 (Vyxeos®; daunorubicin and cytarabine liposome for injection), a dual-drug liposomal encapsulation of cytarabine [C] and daunorubicin [D] at a synergistic ratio, is approved by the FDA and EMA for the treatment of adults with newly diagnosed t-AML or AML with myelodysplasia-related changes. In a phase 3 study (NCT01696084) in older patients (pts; 60-75 y) with newly diagnosed high-risk/secondary AML, CPX-351 significantly improved OS vs 7+3, with a comparable safety profile. An exploratory analysis of the phase 3 study compared outcomes in the subgroup of pts with t-AML who achieved complete remission (CR) or CR with incomplete neutrophil or platelet recovery (CRi). Pts were randomized 1:1 to receive 1-2 induction cycles with CPX-351 (100 units/m2 [C 100 mg/m2 + D 44 mg/m2] as a 90-min infusion on Days 1, 3, and 5 [2nd induction: Days 1 and 3]) or 7+3 (C 100 mg/m2/day continuously for 7 d [2nd induction: 5 d] + D 60 mg/m2 on Days 1-3 [2nd induction: Days 1-2]). Pts achieving CR+CRi could receive up to 2 consolidation cycles with CPX-351 (65 units/m2 [C 65 mg/m2 + D 29 mg/m2] on Days 1 and 3) or 5+2 (as in 2nd induction). Pts could receive hematopoietic cell transplantation (HCT) at the physician's discretion. t-AML was diagnosed in 63/309 (20%) enrolled pts; 14/30 (47%) receiving CPX-351 and 12/33 (36%) receiving 7+3 achieved a CR+CRi (odds ratio = 1.53 [95% CI: 0.56-4.20]). Fewer pts with CR+CRi after CPX-351 vs 7+3 had received prior non-anthracycline chemotherapy alone (CPX-351: 2 [14%] vs 7+3: 5 [42%]), whereas prior radiation therapy alone was less frequent in 7+3 pts (5 [36%] vs 2 [17%]). Median OS was longer for CPX-351 vs 7+3 in t-AML pts with CR+CRi (Figure 1). The HCT rate in pts with CR+CRi was similar for CPX-351 and 7+3 (57% vs 58%; relative risk = 0.97 [95% CI: 0.50-1.90]); however, OS landmarked from the HCT date was longer for CPX-351 (Figure 2). No pt relapsed prior to HCT. Median OS in pts with CR+CRi but no HCT was not reached for CPX-351 vs 8.48 mo for 7+3. The safety profile of CPX-351 vs 7+3 is shown in Table 1. Among t-AML pts who achieved CR+CRi, CPX-351 improved median OS overall and OS landmarked from the HCT date vs 7+3. The CPX-351 safety profile in this subgroup was generally consistent with the known profile of 7+3. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
45. Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis.
- Author
-
Ryan, Daniel H., Newell, Laura F., Ritchie, Ellen K., Strickland, Stephen A., Hogge, Donna E., Solomon, Scott R., Schiller, Gary J., Wieduwilt, Matthew J., Ryan, Robert J., Faderl, Stefan, and Cortes, Jorge E.
- Subjects
- *
ACUTE myeloid leukemia , *LIPOSOMES , *CYTOGENETICS , *MYELODYSPLASTIC syndromes , *CELL transplantation , *ODDS ratio , *PHYSICIANS - Abstract
The WHO 2016 AML-MRC designation applies to AML patients (pts) with a history of myelodysplastic syndrome (MDS) or MDS/myeloproliferative neoplasm, a MDS-related cytogenetic abnormality, or multilineage dysplasia in >50% of ≥2 cell lineages in the absence of NPM1 or biallelic CEBPA mutations. AML-MRC pts typically have a poor prognosis after induction chemotherapy. CPX-351 (Vyxeos®; daunorubicin and cytarabine liposome for injection), a dual-drug liposomal encapsulation of cytarabine [C] and daunorubicin [D] at a synergistic ratio, is approved by the FDA and EMA for the treatment of adults with newly diagnosed therapy-related AML or AML-MRC. A phase 3 study (NCT01696084) in older pts (60-75 y) with newly diagnosed high-risk/secondary AML found that CPX-351 significantly improved median overall survival (OS) vs conventional 7+3, with a comparable safety profile. An exploratory subgroup analysis of the phase 3 study compared outcomes in pts with AML-MRC who achieved complete remission (CR) or CR with incomplete neutrophil or platelet recovery (CRi). Pts were randomized 1:1 to receive 1-2 induction cycles with CPX-351 (100 units/m2 [C 100 mg/m2 + D 44 mg/m2] as a 90-min infusion on Days 1, 3, and 5 [2nd induction: Days 1 and 3]) or 7+3 (C 100 mg/m2/d continuously for 7 d [2nd induction: 5 d] + D 60 mg/m2 on Days 1-3 [2nd induction: Days 1-2]). Pts achieving CR or CRi could receive up to 2 consolidation cycles with CPX-351 (65 units/m2 [C 65 mg/m2 + D 29 mg/m2] on Days 1 and 3) or 5+2 (as in 2nd induction). Pts could receive hematopoietic cell transplantation (HCT) at the physician's discretion. AML-MRC was diagnosed in 246/309 (80%) enrolled pts (123 pts/arm). More AML-MRC pts achieved CR+CRi with CPX-351 (59/123 [48%] vs 40/123 [33%]; odds ratio = 1.83 [95% CI: 1.09-3.09]). Median OS in pts with AML-MRC who achieved CR+CRi was longer with CPX-351 vs 7+3 (Figure 1). The HCT rate in AML-MRC pts with CR+CRi was 54% with CPX-351 vs 43% with 7+3 (relative risk = 1.18 [95% CI: 0.79-1.76]), and OS landmarked from the HCT date was longer with CPX-351 (Figure 2). The safety profile was similar between arms (Table 1), except CPX-351 was associated with longer recovery of neutrophils to ≥500/μL (35 vs 29 d) and platelets to ≥50,000/μL (37 vs 28 d) vs 7+3 in pts who received 1 induction. CPX-351 improved median OS overall and OS landmarked from the HCT date vs 7+3 chemotherapy in AML-MRC pts who achieved CR+CRi. The CPX-351 safety profile in this subgroup was consistent with the overall study population and known profile of 7+3. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
46. Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML) with Prior Hypomethylating Agent (HMA) Exposure Who Achieved Remission.
- Author
-
Lin, Tara, Ryan, Daniel H., Ritchie, Ellen K., Strickland, Stephen A., Hogge, Donna E., Solomon, Scott R., Kolitz, Jonathan E., Schiller, Gary J., Wieduwilt, Matthew J., Ryan, Robert J., Faderl, Stefan, and Cortes, Jorge E.
- Subjects
- *
ACUTE myeloid leukemia , *LIPOSOMES , *FEBRILE neutropenia , *MYELODYSPLASTIC syndromes , *HEMATOLOGIC malignancies , *CELL transplantation , *MEDICATION safety - Abstract
Patients (pts) with newly diagnosed sAML may have previously received HMA therapy for an antecedent hematologic malignancy (eg, myelodysplastic syndrome [MDS]). Outcomes for pts with MDS who progress following HMA therapy are typically poor, with remission rates <30% and overall survival (OS) of ∼6 mo. CPX-351 (Vyxeos®; daunorubicin and cytarabine liposome for injection), a dual-drug liposomal encapsulation of cytarabine [C] and daunorubicin [D] at a synergistic ratio, is approved by the FDA and EMA for the treatment of adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes. In a phase 3 study (NCT01696084) in older pts (60-75 y) with newly diagnosed high-risk/sAML, treatment with CPX-351 significantly improved OS vs 7+3, with a comparable safety profile. An exploratory subgroup analysis of the phase 3 study was performed to compare outcomes in pts with any prior HMA exposure who achieved complete remission (CR) or CR with incomplete neutrophil or platelet recovery (CRi). Pts were randomized 1:1 to receive 1-2 induction cycles with CPX-351 (100 units/m2 [C 100 mg/m2 + D 44 mg/m2] as a 90-min infusion on Days 1, 3, and 5 [2nd induction: Days 1 and 3]) or 7+3 (C 100 mg/m2/d continuously for 7 d [2nd induction: 5 d] + D 60 mg/m2 on Days 1-3 [2nd induction: Days 1-2]). Pts achieving CR+CRi could receive up to 2 consolidation cycles with CPX-351 (65 units/m2 [C 65 mg/m2 + D 29 mg/m2] on Days 1 and 3) or 5+2 (as in 2nd induction). Pts could receive hematopoietic cell transplantation (HCT) at the physician's discretion. Of 309 pts enrolled, 133 (43%) had received prior HMAs; Of these, 23/62 (37%) receiving CPX-351 and 20/71 (28%) receiving 7+3 achieved CR+CRi (odds ratio [OR] = 1.50 [95% CI: 0.73-3.12]) and were included in this analysis. Baseline characteristics were balanced between treatment arms. In pts with prior HMAs who achieved CR+CRi, median OS was longer with CPX-351 (Figure 1). Of note, median OS was also longer with CPX-351 (26.32 vs 10.43 months) in pts without prior HMAs. More pts with prior HMAs who achieved CR+CRi with CPX-351 vs 7+3 underwent HCT (57% vs 35%; relative risk = 1.39 [95% CI: 0.73-2.67]), and OS landmarked from the HCT date was longer with CPX-351 vs 7+3 (Figure 2). The safety profile was generally comparable between treatment arms in pts with prior HMAs who achieved CR+CRi. The most common serious treatment-emergent adverse events were febrile neutropenia (CPX-351: 13%; 7+3: 10%), ejection fraction decreased (9%; 10%), and subdural hemorrhage (0%; 10%). There was no early mortality by Day 60 in either arm. Among pts who had prior HMA exposure and achieved CR+CRi, CPX-351 improved median OS, the rate of HCT, and median OS landmarked from the HCT date vs 7+3. The CPX-351 safety profile in this subgroup was consistent with the overall study population and the known profile of 7+3. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.